New Drug Transfer in Europe and America
Release time:
2024-10-25
In countries such as Europe, the United States, Japan or India, their drug research and development technology is becoming more and more mature, and their research and development institutions have developed new drugs that are in the clinical stage or on the market. Through its resources in Europe and the United States, Delsalt can help companies obtain new drug transfer information from R & D institutions in the United States, Europe and Japan.
1. New Drug Technology Transfer
In countries such as Europe, the United States, Japan or India, their drug research and development technology is becoming more and more mature, and their research and development institutions have developed new drugs that are in the clinical stage or on the market. Through its resources in Europe and the United States, Delsalt can help companies obtain new drug transfer information from R & D institutions in the United States, Europe and Japan.
As a scarce resource, new drugs will have a huge impact on the long-term development of enterprises. A good variety may change an enterprise. At present, the main new drug development comes from the United States and Europe, and the global new drug production cycle will become longer and longer. Therefore, a good new drug variety is an important way for enterprises to survive and develop. Customers should grasp the opportunity according to their own needs and choose New drug products.
2. New Drug Transfer Process
1. The enterprise can provide the choice direction, and Durst obtains the relevant new drug transfer information;
2. The enterprise signs a transfer contract with the research and development unit;
3. Complete the relevant patent and technology transfer;
4. Continue clinical development (different clinical stages);
Completion of clinical trials;
6. New drug declaration;
New drug approvals;
8. Obtain new drug registration approval in China.
3. considerations
1. Which type of new drug is less risky?
2. How long does the development cycle of a new drug generally take?
3. How are new drugs from the United States or Europe introduced into China?
Previous
Next
Previous:
Next:
Related Content
Plant design engineering construction management
Combined with the rich experience of the project team, the verification system and GMP system are optimized and improved according to the existing configuration and operation of the enterprise. Durst advocates the introduction of new verification ideas and concepts in Europe and the United States to promote project implementation:
2024-10-25
The formation of the quality of any drug is designed and produced, not tested. How to ensure that the quality of the product remains stable and high quality?
2024-10-25
Products registered in Europe and America
Durst (Delsalt) is a global pharmaceutical consulting company, maintaining exchanges and contacts with multiple industry associations in Europe and the United States. We have a wealth of global drug information resources, including solid oral preparations, injections, eye drops, and topical products. Durst has rich experience in the registration of products in developed countries such as the European Union and the United States, and has helped many pharmaceutical companies to complete the registration of products in the European Union and the United States. According to the needs of pharmaceutical companies, to help pharmaceutical companies through different ways to enter the developed European and American markets.
2024-10-25
European and American drug OEM
As a Spanish global consulting company, Delsalt has a wealth of product resources in Europe and the United States to meet the OEM needs of major customers in the current market. Entrusted processing (Original Equipment Manufacturer,OEM)& contract processing outsourcing (Contract Manufacture Organization,CMO): European drug listing license holding companies, entrusted to Chinese pharmaceutical enterprises production, entrusted companies to assist Chinese pharmaceutical enterprises to obtain EU GMP certification, production of drugs sold to the entrusted company, by the entrusted company sold to EU member states.
2024-10-25
New Drug Transfer in Europe and America
In countries such as Europe, the United States, Japan or India, their drug research and development technology is becoming more and more mature, and their research and development institutions have developed new drugs that are in the clinical stage or on the market. Through its resources in Europe and the United States, Delsalt can help companies obtain new drug transfer information from R & D institutions in the United States, Europe and Japan.
2024-10-25
QP Declaration of Conformity is a formal declaration of GMP conformity in the clinical phase of the product in the EU and PIC/S Member States, which has the effect of legal recognition, and the inspection in the clinical phase is equivalent to the official inspection. The QP shall be responsible for the GMP implementation results of the enterprise. In the clinical phase, the QP conformity statement can be submitted as GMP conformity data in the clinical phase to the EU or PIC/S countries as the basis for GMP conformity. The QP declaration of conformity is also a very good proof of compliance before the enterprise has not obtained the official GMP certificate overseas. According to the EU QP regulation, except in special circumstances, the QP declaration of conformity needs to be checked remotely, the enterprise or local government provides proof, and the QP should go to the site for review.
2024-10-25
Contact Information
Durst (Shenzhen) Consulting Service Co., Ltd.
Contact Phone:86-18826007039
E-mail:consulting@delsalt.com
Address: C19, Building 1, Yongheyuan, Zhuangbian Community, xixiang street, Bao 'an District, Shenzhen City, Guangdong Province
Sweep to identify concerns:
Scan attention consultation